[Liquid biopsy analysis using cell-free DNA (cfDNA): Opportunities and limitations].

摘要: Molecular biological analysis of nucleic acids in blood or other bodily fluids (i.e. liquid biopsy analyses) may supplement the pathologists' diagnostic armamentarium a reasonable way-particularly cancer precision medicine. Within field oncology, can potentially be used to monitor tumor burden and early detect emerging resistance course targeted therapies. An already approved application is detection epidermal growth factor receptor (EGFR) driver mutations samples lung patients those cases where no tissue available. However, there still currently considerable insecurity associated with blood-based DNA analytic methods that must solved before implemented for broader routine diagnosis cancer. In this article, current state development molecular diagnostics from pathology point view presented.